source
- FDA finds Replimune's melanoma data package uninterpretable, foreshadows tough advisory committee reviewThe FDA has deemed the single-arm mid-stage study submitted by Replimune for its oncolytic immunotherapy RP1 as not interpretable, raising concerns ahead of an upcoming advisory committee meeting.…
- Claris Bio raises $118M Series B and appoints new CEO to advance eye-drug for limbal stem cell deficiencyClaris Bio, a New Jersey biotechnology company, announced a $118 million Series B financing round co-led by Samsara BioCapital and Catalio Capital Management, with participation from Sofinnova Inve…